Everything below concerns HGF/c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Axatilimab, sold under the brand name Niktimvo, is a monoclonal antibody used for the treatment of chronic graft-versus-host disease. It is a blocker of the colony stimulating factor-1 receptor. It is given by injection into a vein. The most common side effects include infections; increased blood level of liver enzymes; decreased blood level of phosphate; low red blood cell count (anemia); muscle, bone, or joint pain; increased blood level of pancreatic enzymes; low energy; increased blood level of calcium; increased blood level of a muscle enzyme; increased blood level of a bone enzyme; nausea; headache; diarrhea; cough; fever; shortness of breath; and infusion related reactions. Infusion-related reactions are common and can be serious. Axatilimab was approved for medical use in the United States in August 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
The fledgling is employed by Sebastian LaCroix (voiced by Andy Milder), prince of Los Angeles's vampires. The fledgling's travels through the vampire world bring them into contact with other undead creatures such as the deformed information broker Bertram Tung, the anarch Smiling Jack (John DiMaggio), and the dissociative Voerman sisters, Jeanette and Therese. Chinatown is controlled by the Kuei-Jin, Asian vampires led by Ming-Xiao, who do not require blood and consider themselves superior to other vampires.
== Distribution and habitat == Panaeolus cyanescens is a coprophilous (dung-inhabiting) species which occurs in both the Neotropics and Paleotropics. It has been found in Vietnam, Africa (including South Africa, Mauritius, Madagascar and Democratic Republic of the Congo), Australia, Belize, the Caribbean (Bermuda, Grenada, Barbados Jamaica, Trinidad, and Puerto Rico), Costa Rica, India, Malaysia, Indonesia, Sri Lanka, Cambodia, Thailand, Japan, Mexico, Oceania (Fiji and Samoa), the Philippines, South America (Bolivia, Brazil, Paraguay, Colombia, Venezuela, and Ecuador), South Korea, and the United States (California, Hawaii, Louisiana, Mississippi, Alabama, Florida, Tennessee, Texas, Kentucky, Virginia, Georgia, and North Carolina).
Sources: en.wikipedia.org
The presence of ptaquiloside has been detected in a variety of ferns, including the species in the genera Pteridium (bracken), Pteris, Microlepia, and Hypolepis. Pteridium aquilinum (commonly known as bracken fern) is the most common ptaquiloside-containing fern with a wide geographical and ecological distribution. It is present in all continents from subtropic to subarctic areas. Bracken fern is a very adaptable plant and is capable of forming dense, rapidly expanding populations in course of the first phases of the ecological succession in forest cleanings and other disturbed rural areas. Its aggressive growth, characterized by an extensive rhizome system and rapidly growing fronds, sometimes enables it to be a dominant species in certain plant communities. The ptaquiloside content of bracken varies widely across species and changes with the part of the plant, the plant growing site and the collecting season. According to previous studies, the concentrations of ptaquiloside in bracken varied between 0 and 1% of the dry weight of the plant. Generally, ptaquiloside is found to occur in the highest concentrations in the young developing parts of bracken, such as the croziers and unfolding parts during the spring and early summer, while the concentrations of ptaquiloside in the rhizomes are rather low. However, studies on the concentrations of ptaquiloside in Danish bracken by Rasmussen et al. showed that the concentrations of ptaquiloside in the rhizomes were significantly higher than the previously reported values.
== Writers == Clement Clarke Moore (1798), purported author of A Visit From St. Nicholas Robert Charles Sands (1815), poet and writer Charles Fenno Hoffman (1825), poet, translator, and editor, founder of The Knickerbocker magazine Cornelius Mathews* (1834), writer of the Young America movement Evert Augustus Duyckinck (1835), literary biographer in the Young America movement George Templeton Strong (1838), noted diarist; founder of the United States Sanitary Commission and the Union League Club of New York Edgar Fawcett (1867), novelist William Dudley Foulke (1869), literary critic, journalist, and reformer; former United States Civil Service Commission commissioner Duffield Osborne (1879), author John Kendrick Bangs (1883), author, satirist, editor of Puck magazine John Armstrong Chaloner (1883), writer and activist, brother of Lewis Stuyvesant Chanler and William A.
That same year, Sonic Healthcare acquired 56% ownership of the Schottdorf Group in Germany, 72% ownership of the Independent Practitioner Network Limited (IPN), the pathology operations of Endeavour HealthCare in NSW and WA merging them into Douglass Hanly Moir Pathology and Clinipath Pathology, and (through IPN) Endeavour's medical centre operations. In 2005, Sonic Healthcare acquired an 82% interest in Clinical Pathology Laboratories, Inc., the largest privately owned regional pathology laboratory in the United States.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.